Mallinckrodt (NYSE:MNK): Neutral Rating was Kept by Research Analysts at B. Riley FBR; with Target Price per Share of $20.

June 29, 2018 - By Rebecca Betts

During 2018 Q1 the big money sentiment increased to 0.9. That’s change of 0.19, from 2017Q4’s 0.71. 38 investors sold all, 85 reduced holdings as Mallinckrodt Public Limited Company ratio improved. 64 grew stakes while 47 funds amassed stakes. Funds hold 96.44 million shares thus 6.30% more from 2017Q4’s 90.73 million shares.

Parkside Bancorp Tru holds 0% of its capital in Mallinckrodt Public Limited Company (NYSE:MNK) for 331 shs. Burt Wealth Advsrs invested in 14 shs or 0% of the stock. Alliancebernstein L P accumulated 0.03% or 2.53 million shs. Qs Ltd Limited Liability Company has 6,436 shs for 0% of their capital. Vantage Investment Advsrs Llc stated it has 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Virginia Retirement Et Al has 12,100 shs. Lingohr Partner Asset Gmbh reported 40,581 shs. 84,600 were accumulated by Gvo Asset Mngmt Limited. Raymond James & Associates stated it has 14,787 shs or 0% of all its holdings. Moreover, First Trust Advsr Limited Partnership has 0.03% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 986,543 shs. Valley Advisers has 0% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 4 shs. Pinnacle Associates Ltd, a New York-based fund reported 11,580 shs. Jabodon Pt reported 222,819 shs. Prudential Fincl Inc has 0.02% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 861,097 shs. Federated Pa invested in 79,252 shs.

Mallinckrodt Public Limited Company had 1 sale and 1 insider purchase since May 9, 2018. This’s net activity of $4.14 million. 3,000 Mallinckrodt Public Limited Company (NYSE:MNK) shs with value of $46,615 were bought by Trudeau Mark.

Reiterated Mallinckrodt (NYSE:MNK) Rating.

Mallinckrodt (NYSE:MNK)‘s stock Neutral rating was maintained at B. Riley FBR on Thursday, 28 June. The broker’s Equities researchers have a $20 target price and gives a potential upside of 7.18 % on the stock.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Coverage

In total 12 analysts cover Mallinckrodt (NYSE:MNK). “Buy” rating has 4, “Sell” are 1, while 7 are “Hold”. (NYSE:MNK) has 33% bullish analysts. 22 are the (NYSE:MNK)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Tuesday, February 6 the stock has “Buy” rating by BMO Capital Markets. On Tuesday, February 27 the rating was maintained by Jefferies with “Buy”. In Thursday, April 26 report Mizuho maintained it with “Hold” rating and $1500 target. On Wednesday, May 9 Morgan Stanley maintained the shares of MNK in report with “Equal-Weight” rating. On Tuesday, January 9 the stock has “Hold” rating by Mizuho. The stock rating was maintained by Canaccord Genuity with “Hold” on Tuesday, March 6. On Friday, April 20 Mizuho maintained Mallinckrodt Public Limited Company (NYSE:MNK) rating. Mizuho has “Hold” rating and $1500 target. On Monday, April 23 the company was maintained by Leerink Swann. On Tuesday, February 27 Cantor Fitzgerald maintained the shares of MNK in report with “Buy” rating. On Tuesday, May 8 the firm earned “Buy” rating by Cantor Fitzgerald.

Ticker’s shares touched $18.66 during the last trading session after 2.71% change.Currently Mallinckrodt Public Limited Company is downtrending after 59.76% change in last June 29, 2017. MNK has also 1.25 million shares volume. MNK underperformed the S&P500 by 72.33%.

On August, 14 is anticipated Mallinckrodt Public Limited Company (NYSE:MNK)’s earnings report, as reported by Faxor. The earnings per share diference is $0.36 or 19.46 % down from last years number. Previous year: $1.85; Analysts forcast: $1.49. If reported the P/E will be 3.13 with $123.77 million profit. After $1.31 earnings per share was published previous quarter, analysts now see EPS growth of 13.74 % for Mallinckrodt Public Limited Company.

Mallinckrodt public limited company develops, makes, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions.The firm is valued at $1.55 billion. The firm markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.The P/E ratio is 1.02. It offers H.P.

More recent Mallinckrodt Public Limited Company (NYSE:MNK) news were announced by Streetinsider.com, Streetinsider.com and Seekingalpha.com. The first one has “Mallinckrodt (MNK) Reports Complete Enrollment Target for Rheumatoid Arthritis Phase 4 Clinical Study for HP Acthar …” as a title and was announced on June 28, 2018. The next is “Aurobindo Said in Advanced Talks to buy Mallinckrodt’s (MNK) Specialty Generics Business – CNBC-TV18” on June 28, 2018. And last was announced on June 08, 2018, called “Mallinckrodt: The Cheapest Stock In Global Healthcare”.

Mallinckrodt Public Limited Company (NYSE:MNK) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: